Withdrawal of European Marketing Authorization Application for ivosidenib for relapsed or refractory IDH1-mutant acute myeloid leukaemia
The decision to withdraw was based on feedback from the European Medicine Agency’s that the available clinical data, an uncontrolled Phase 1 study, did not sufficiently support a positive benefit-risk balance.
Source:
Biospace Inc.